Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2024-11-25 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
可转换公司债券付息公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the interest payment on a convertible bond issued by Lingkang Pharmaceutical Group Co., Ltd. It includes specifics such as bond code, interest payment dates, interest rates, tax information, and procedural details for bondholders. The content focuses on the payment of interest on convertible bonds, including dates for record, ex-dividend, and payment, as well as tax treatment and contact information. There is no indication that this is a full financial report, audit report, or earnings release. It is not a regulatory filing or certification letter, but a formal announcement about bond interest payment. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities, including bond interest payments.
2024-11-25 Chinese
关于收到上海证券交易所2024年第三季度报告信息披露的监管工作函的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the receipt of a regulatory work letter from the Shanghai Stock Exchange about the company's 2024 third quarter report disclosure. The text discusses the regulatory letter's content and the company's plan to respond and fulfill disclosure obligations. The document is short (1222 characters) and does not contain actual financial statements or detailed financial data but rather is an announcement about receiving a regulatory inquiry related to the quarterly report. According to the 'MENU VS MEAL' rule and the nature of the content, this is not the quarterly report itself but an announcement related to regulatory disclosure. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-11-22 Chinese
关于子公司注射用头孢呋辛钠通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Lingkang Pharmaceutical Group Co., Ltd. regarding its subsidiary's drug "Cefuroxime Sodium for Injection" passing the generic drug consistency evaluation. It includes regulatory approval details from the National Medical Products Administration, drug specifications, production and registration information, and the impact and risk warnings related to the drug's market competitiveness. The document is relatively short (3061 characters) and is an announcement of regulatory approval and business impact rather than a detailed financial report or management discussion. It does not contain financial statements, earnings data, or detailed management analysis. It is not a report of voting results, nor a call transcript, nor a capital update. It is a regulatory announcement about product approval and related business impact. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-11-05 Chinese
2024年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '灵康药业集团股份有限公司 2024 年第三季度报告' which translates to 'Lingkang Pharmaceutical Group Co., Ltd. 2024 Third Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes for the third quarter of 2024. The report explicitly states it is unaudited and covers the quarter ending September 30, 2024. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is over 12,000 characters, and it contains substantive financial data, not just an announcement or certification. Therefore, the correct classification is 'IR' for Interim / Quarterly Report. 9M 2024
2024-10-30 Chinese
可转债转股结果暨股份变动公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the results of convertible bond conversions and related changes in share capital. It details the amount of convertible bonds converted into shares during a specific period, cumulative conversion amounts, and the resulting changes in share capital. The document includes specific bond codes, conversion prices, and dates, and it is structured as an official disclosure to shareholders and the market. The content focuses on convertible bond conversion results and share capital changes rather than financial performance, management changes, or other report types. Given the nature of the announcement about convertible bond conversion results and share capital changes, the most appropriate classification is "POS" (Transaction in Own Shares), which covers reports of the company buying back or issuing shares, including convertible bond conversions leading to share issuance. The document length is 1666 characters, which is short but contains substantive information about share transactions, not merely an announcement of a report publication or a certification. Therefore, it is not RPA or RNS.
2024-10-09 Chinese
关于控股股东股票质押式回购交易延期购回的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the extension of the repurchase period for a stock pledge transaction by the controlling shareholder. It details the number of shares pledged, the extension dates, and the impact on the company. There is no financial statement, no detailed financial analysis, and no mention of an annual or interim report. The document is short (2023 characters) and serves as a regulatory disclosure about a financing-related event (stock pledge extension). This fits best under Capital/Financing Update (CAP) as it relates to financing activities and capital structure changes. It is not a report publication announcement or regulatory filing because it contains substantive information about the financing event itself.
2024-09-24 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.